Haihe Biopharma Co., Ltd.
Clinical trial pipeline · active industry-sponsored Phase 1/2 to Phase 3 trials · updated 2026-11-18
ACTIVE TRIALS5
PHASE 3 / 2-30
RECRUITING4
READOUTS ≤12 MONTHS0
| TRIAL | PHASE | STATUS | CONDITION | N | PRIMARY COMPLETION |
|---|---|---|---|---|---|
| Glumetinib NCT04270591 |
P1/2 | Recruiting | C-Met Exon 14 Mutation | 183 | 2023-10-25 |
| CYH33 NCT05043922 |
P2 | Active, not recruiting | Ovarian Cancer; Recurrent Cancer | 93 | 2024-07-31 (+13 mo) |
| HH2853 Tablets NCT06909877 |
P1/2 | Recruiting | Relapsed/Refractory Peripheral T-Cell Lymphoma (R/R PTCL) | 100 | 2025-10-31 |
| HH2853 Tablets NCT04390737 |
P1/2 | Recruiting | FL Lymphoma; Epithelioid Sarcoma | 254 | 2027-12-31 (+82 mo) |
| CYH33 NCT06975618 |
P1/2 | Recruiting | PIK3CA-Related Overgrowth Spectrum (PROS); PIK3CA-related Vascular Malformations (PRVM) | 141 | 2029-12-31 |